Comparative Pharmacology
Head-to-head clinical analysis: ADHANSIA XR versus BENZEDRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADHANSIA XR versus BENZEDRINE.
ADHANSIA XR vs BENZEDRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adhansia XR is a central nervous system (CNS) stimulant. The mechanism of action in attention deficit hyperactivity disorder (ADHD) is not fully known, but it is thought to involve blockade of norepinephrine and dopamine reuptake into presynaptic neurons, increasing their levels in the synaptic cleft. This enhances attention and reduces impulsivity.
Benzedrine (racemic amphetamine) releases dopamine and norepinephrine from presynaptic neurons, blocks their reuptake, and inhibits monoamine oxidase, increasing synaptic monoamine levels.
Methylphenidate hydrochloride extended-release: Oral, 18-72 mg once daily in the morning.
Oral: 5-10 mg once or twice daily, maximum 40 mg/day. Intramuscular: 5-10 mg every 30-60 minutes as needed, maximum 40 mg/day.
None Documented
None Documented
Mean terminal elimination half-life is 7.5 hours (range 5-10 hours) following oral administration, allowing twice-daily dosing.
Terminal elimination half-life: 4-6 hours in adults (range 4-8 hours). Clinically, duration of action correlates with half-life, but tolerance may develop with repeated dosing.
Primarily renal (78% as unchanged drug), with 10% biliary/fecal elimination.
Renal (30-40% unchanged, pH-dependent), with minor biliary/fecal elimination. At acidic urine pH, elimination half-life is shortened; at alkaline pH, reabsorption increases.
Category C
Category C
CNS Stimulant
CNS Stimulant